Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 3/20 | 0.43 |
| ▸ | APEX1 | P27695 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | ALB | P02768 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | IL2 | P60568 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.36 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24311576 | 1.00 | CYP1A2 (0.44) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| SCHEMBL1325154 | 0.86 | FPR2 (0.54) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| SCHEMBL1325155 | 0.86 | FPR2 (0.54) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| Hydrochloric Acid SCHEMBL2521612 | 0.84 | FPR2 (0.52) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| SCHEMBL14037245 | 0.84 | FPR2 (0.46) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| SCHEMBL8717678 | 0.84 | FPR2 (0.46) | CYP1A2CYP2D6FPR2APEX1PMP22 | |
| SCHEMBL12668874 | 0.84 | ACACB (0.46) | ESR1ESR2ALDH1A1 | |
| SCHEMBL16327905 | 0.84 | ESR1 (0.40) | ESR1ESR2ALDH1A1 | |
| SCHEMBL9886030 | 0.84 | ACACB (0.46) | ESR1ESR2ALDH1A1 | |
| SCHEMBL7637685 | 0.84 | ESR1 (0.56) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106361-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PAICS, CYCS, LSS | CYP1A2 140/4885CYP2D6 101/4885FPR2 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.